Navigation Links
David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
Date:8/4/2008

DURHAM, N.C., Aug. 4 /PRNewswire/ -- Regado Biosciences today announced the appointment of David J. Mazzo, Ph.D., as President and Chief Executive Officer (CEO), effective immediately. Dr. Mazzo brings to Regado almost 25 years of experience in the pharmaceutical industry, most recently as President and CEO of AEterna Zentaris. Dr. Mazzo also has served as President and CEO of Chugai Pharma USA, LLC, the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan, a member of the Roche Group. Dr. Mazzo replaces Regado co- founder Douglas Gooding.

Dennis Podlesak, Chairman of the Board of Regado, stated, "Dr. Mazzo's appointment comes at an important growth phase for the Company. The data from our ongoing Phase IIa study of the REG1 Anticoagulation System are expected later this year. This is the first study of the REG1 system in patients undergoing percutaneous coronary intervention. Dr. Mazzo's senior leadership experience, his strong scientific background and commercial and regulatory expertise will be invaluable to the Company as Regado advances and expands its clinical development programs."

Throughout his career in the pharmaceutical industry, Dr. Mazzo has acquired a thorough understanding of the drug development process from discovery through manufacturing, launch and commercialization. Prior to joining Chugai, Dr. Mazzo held positions of increasing responsibility with Merck & Co., Baxter, Rhone-Poulenc Rorer, Hoechst Marion Roussel, and Schering-Plough.

Dr. Mazzo commented, "I am excited for the opportunity to lead Regado through its next stage of growth. My primary goals are to build upon the Company's established success and further harness the great potential in Regado's lead programs and discovery platform. The Company is unique in its focus on developing aptamer therapeutics paired with agents that can directly modulate their activity. This has the potential to provide unprecedented control to the physician and represents an evolution for patient care in the hospital setting."

Dr. Mazzo currently is Non-Executive Chairman of Psivida, Inc. and a Director of Avanir Pharmaceuticals. He earned a Bachelor of Arts degree in the Honors Program (Interdisciplinary Humanities) and a Bachelor of Science degree in Chemistry from Villanova University. In addition, Dr. Mazzo received his Master of Science degree in Chemistry and his Ph.D. degree in Analytical Chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the discovery and development of drug:antidote systems. These systems comprise aptamer therapeutics that can be directly controlled by a specific and matched oligonucleotide agent. Regado's technology is designed to give physicians the ability to directly control and fine tune each product's therapeutic effect. This control and flexibility allows physicians to meet the individual needs of each patient independent of the setting. A spin-out of the Department of Surgery at Duke University Medical Center, Regado was created to answer the therapeutic needs identified by its scientific founders and clinical advisors.

The Company's proprietary platform technology enables the discovery of oligonucleotide-based drug-modulating pairs to any target protein. Regado initially is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles.

Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin.


'/>"/>
SOURCE Regado Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NSF International Acquires David Begg Associates
2. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
3. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
4. David Barker, Former Illumina CSO, Joins GenVaults Scientific Advisory Board
5. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
6. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
7. Immunosyn Corporation Names G. David Criner as CFO
8. Pasteuria Bioscience Taps New CEO David N. Duncan
9. David Mott Appointed Non Executive Director at Shire
10. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
11. Transgenomic Appoints David Pauluzzi to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):